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Recommended by Peter Stockwell
MODULAR ANALYTICS Serum Work Area (in USA Integrated MODULAR ANALYTICS, MODULAR ANALYTICS is a trade-
mark of a member of the Roche Group) represents a further approach to automation in the laboratory medicine. This instrument
combines previously introduced modular systems for the clinical chemistry and immunochemistry laboratory and allows cus-
tomised combinations for various laboratory workloads. Functionality, practicability, and workﬂow behaviour of MODULAR
ANALYTICS Serum Work Area were evaluated in an international multicenter study at six laboratories. Across all experiments,
236000 results from 32400 samples were generated using 93 methods. Simulated routine testing which included provocation inci-
dentsandanomaloussituationsdemonstratedgoodperformanceandfullfunctionality.Heterogeneousimmunoassays,performed
on the E-module with the electrochemiluminescence technology, showed reproducibility at the same level of the general chemistry
tests, which was well within the clinical demands. Sample carryover cannot occur due to intelligent sample processing. Workﬂow
experiments for the various module combinations, with menus of about 50 assays, yielded mean sample processing times of <38
minutes for combined clinical chemistry and immunochemistry requests; <50 minutes including automatically repeated samples.
MODULAR ANALYTICS Serum Work Area oﬀered simpliﬁed workﬂow by combining various laboratory segments. It increased
eﬃciency while maintaining or even improving quality of laboratory processes.
Copyright © 2008 Paolo Mocarelli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The clinical laboratory is arguably the frontrunner in apply-
ing scientiﬁc discoveries and technical innovations to patient
care. For example, there are not only far more tests read-
ily available now compared to just twenty years ago but also
the tests themselves have increased sensitivity and speciﬁcity
(e.g., hs-CRP, ferritin). It has been estimated that about 65%
of medical decisions are based on laboratory tests [1].
Paradoxically, the clinical laboratory success has placed
it under even greater pressure to produce more and better
testresults,withshorterturnaroundtimesandatlowercosts.
As clinical laboratories have evolved, they have relied heav-
ily on automation. By moving from manual assays of single
analytes to random access, multichannel, automated instru-
ments, and more tests can be done, more frequently, with
fewer people. As noted in recent publications, by combin-
ing several of these instruments into a novel single platform2 Journal of Automated Methods and Management in Chemistry
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Figure 1: Schematic structure of MODULAR system.
for the clinical chemistry [2] and for the immunochemistry
laboratory [3], these analysers represented a new degree of
consolidation.
However, there has been little integration of traditional
clinical chemistry (ISE, spectrophotometry, homogeneous
immunoassay) and heterogeneous immunoassay. From an
analytical and technology perspective, the separation of the
two types of analysers may make sense. But, from a medi-
cal perspective, of course, the separation is entirely artiﬁcial.
For the patient in the emergency room, the physician needs
to know the troponin and the potassium. For the oncology
patient, the physician needs to know the CEA as well as the
calcium. Does it make sense to draw two tubes of blood to
insure quick turnaround time by running the sample on two
analysers simultaneously? Or, if just one tube is drawn, is it
theonlysolutiontoinsurequickturnaroundtimebyaskinga
technologist to make sure that, as soon as the tube is ﬁnished
on the chemistry analyser, it gets placed on the immunoas-
say analyser to be analysed there? With either scenario, there
are inherent ineﬃciencies, as compared to running a single
tube on a single system for all the requested tests. MODU-
LARANALYTICSSWA(inUSA:IntegratedMODULARAN-
ALYTICS, IMA), thereafter MODULAR system, represents
theintegrationofcomprehensivesystemsfortraditionalclin-
ical chemistry and for heterogeneous immunoassays into a
single system for essentially all chemistry analytes.
Herewepresenttheresultsofourstudiesat6laboratories
with a single system processing a selection of 30 to 50 diﬀer-
ent tests for clinical chemistry, speciﬁc proteins, therapeutic
drugs, and immunochemistry determination.
Our goals were to
(1) evaluate the functionality and practicability of the
analyser;
(2) determine whether improved eﬃciency would be re-
alized by integrating clinical chemistry with heteroge-
neous immunoassay testing;
(3) test for possible eﬀects on the quality of results (repro-
ducibility, carryover) due to consolidation.
In addition, we predicted that there would be a reduction of
sample splitting, the elimination of multiple user interfaces,
and a reduction of hands-on labour.
Experiments were performed on MODULAR system in
ﬁve laboratories over a period of ﬁve months. At a sixth site,
a larger hardware conﬁguration was tested afterwards.
2. MATERIALS AND METHODS
MODULAR ANALYTICS Serum Work Area combines pre-
viously evaluated modular systems for clinical chemistry
and immunochemistry: MODULAR ANALYTICS  D,P  and
MODULAR ANALYTICS  E  [2, 3].
The MODULAR system consists of a control unit, a core
unit with a bidirectional multitrack rack transportation sys-
tem, and four kinds of analytical modules—an ISE module
for the electrolytes Na, K, and Cl with a maximum through-
put of 900 tests/hour, a P800 module with a capacity of 44
spectrophotometrictestsonboardandamaximumthrough-
putof800tests/hour,aD2400modulewith16spectrophoto-
metric tests and a maximum throughput of 2400 tests/hour,
and an E170 module using the electrochemiluminescence
technology with a capacity of 25 immunochemistry reagents
on board and a throughput of up to 170 tests/hour. The
conﬁgurations of MODULAR system are versatile and al-
low customised module combinations for various laboratory
workload patterns. Of the several available hardware combi-
nations, three diﬀerent combinations of the clinical chem-
istry modules D and P and the immunochemistry module
E were evaluated at the six sites (3  PE ,2 PPE ,a n d1
 DPE ); all systems included an ISE module. Figure 1 shows
the schematic structure of MODULAR system.
The instruments used in the diﬀerent laboratories for
comparison with MODULAR system during the workﬂow
study were MODULAR ANALYTICS  P ,  PP ,  E ,E l e c -
sys 2010 (Elecsys is a trademark of a member of the Roche
group), Hitachi 747 and 917, all from Roche Diagnostics
(Mannheim, Germany), the BNA II protein analyser from
Dade Behring (Liederbach, Germany), the ADVIA Centaur
and ACS: 180 from Bayer (Tarrytown, NY, USA) and the
AxSYM from Abbott Laboratories, (Abbott Park, Illinois,
USA).
The methods selected for the workﬂow studies covering
a p p r o x i m a t e l y8 0a n a l yt e swi t h3 0t o5 0a p p l i c a t i o n sp e rl a b -
oratory are summarised in Table 1. For the imprecision runs
and functionality testing, only a subset of these methods wasPaolo Mocarelli et al. 3
Table 1: List of analytes used during the performance evaluation and within-run imprecision for selected analytes (cells with a CV number:
analytes were used for within-run imprecision, x: analytes were added for the workﬂow experiments; CS1 control serum PNU from Roche,
HS human serum pool, HU human urine pool, analyte concentrations within or slightly above reference range; CS pool, control serum of a
low- and high-level control).
Assays Method Units Material Lab 1
CV%
Lab 2
CV%
Lab 3
CV%
Lab 4
CV%
Lab 5
CV%
Lab 6
CV%
Qual-Spec
CV%∗
Electrolyte assays
NA Sodium (ISE-indirect) mmol/l CS 1 0.3 0.4 0.3 0.3 0.7 0.4 0.3 (0.7)
K Potassium (ISE-indirect) mmol/l CS 1 0.5 0.5 0.3 0.5 0.8 0.4 2.4
CL Chloride (ISE-indirect) mmol/l CS 1 0.4 0.5 0.4 0.4 0.6 0.5 0.7 (1.0)
Enzyme assays
ACP Acid phosphatase U/l x x 4.5
ALP A Alkaline phosphatase AMP U/l CS 1 0.9 3.4
ALP I Alkaline phosphatase IFCC U/l CS 1 0.7 x 3.4
ALP O Alkaline phosphatase
optimized U / l C S 1 x1 x3 . 4
ALT I Alanine aminotransferase
IFCC, wo Pyp U/l CS 1 2.5 x 2.4 2.4 13.6
ALT IP Alanine aminotransferase
IFCC, w Pyp U/l CS 1 2.5 x 13.6
AST I Aspartate aminotransferase
IFCC wo Pyp U/l CS 1 x 3.3 2.2 2.1 7.2
AST IP Aspartate aminotransferase
IFCC w Pyp U/l CS 1 x 2.1 7.2
AMY
Amylase total EPS
(ethylidene protected
substrate)
U/l CS 1 0.7 x x 0.6 0.6 3.7
P-AMY Amylase pancreatic EPS U/l CS 1 0.8 5.9
CHE
Cholinesterase
(Butyrylthiocholine
substrate)
U/l x x x x 3.5
CK Creatine kinase, NAC
activated (N-acetylcysteine) U/l CS 1 0.6 0.8 x x 0.7 x 20.7
CKMB CK-MB—MB isoenzyme of
creatine kinase U/l CS 1 2.3 x x x
GGT
γ-Glutamyl transferase
(procedure by
Szasz-Persijn)
U/l CS 1 x x 1.8 1.6 x 1.7 7.4
GLDH Glutamate dehydrogenase U/l x x
HBDH Lactate dehydrogenase-1-
isoenzyme U/l x
LDH O Lactate dehydrogenase
DGKC U / l C S 1 x0 . 4 x0 . 7 x3 . 9
LD Lactate dehydrogenase U/l CS 1 1 3.9
LIP Lipase colorimetric U/l CS 1 1 1 0.8 11.6
Substrate assays
ALB Albumin (BCG, bromcresol
green, plus) g/l CS 1 x 0.8 x 1.2 1.1 (2.8)
D-BIL Bilirubin direct
(Jendrassik) μm o l / l C S 1 xxxx1 . 8 x
T-BIL
Bilirubin total (DPD,
dichlorphenyldiazonium
method)
μmol/l CS 1 x x x x 1.9 x 11.3
CHOL Cholesterol (CHOD-PAP) mmol/l CS 1 0.8 1.0 0.9 0.9 1.1 1.4 2.7
HDL High-density lipoproteins mmol/l CS 1 0.8 0.9 x 0.9 x 3.6
LDL Low-density lipoproteins mmol/l CS 1 0.6 x x 3.34 Journal of Automated Methods and Management in Chemistry
Table 1: Continued.
Assays Method Units Material Lab 1
CV%
Lab 2
CV%
Lab 3
CV%
Lab 4
CV%
Lab 5
CV%
Lab 6
CV%
Qual-Spec
CV%∗
CREAJ Creatinine (Jaﬀ´ e, rate
blanked) μmol/l CS 1 2.4 1.4 1.9 1.1 1.8 2.2
CREA Creatinine (enzymatic,
plus)-urine μmol/l x
GLU P Glucose (GOD-PAP) mmol/l CS 1 0.8 0.9 2.2
GLU H Glucose (hexokinase) mmol/l CS 1 0.9 0.7 1.0 1.0 0.6 2.2
FE Iron (FerroZine method) μmol/l CS 1 0.5 x 0.7 1.2 x x 15.9
LACT Lactate (colorimetric) mmol/l CS 1 0.7 0.9 13.6
TP Total protein (biuret
reaction) g / l C S 1 x0 . 4 xx0 . 8 x1 . 4
TG Triacylglycerol (GPO-PAP) mmol/l CS 1 1.1 1.3 0.9 1.2 1.2 0.7 11.5
UREA UREA/BUN (UV, kinetic) mmol/l CS 1 1.8 1.4 1.5 1.6 1.3 1.7 6.3
UA Uric acid (PAP, plus) μmol/l CS 1 x 0.5 1.6 0.6 1.0 1.0 4.2
CO2 Bicarbonate (UV, kinetic) mmol/l CS 1 1.6 2.3 (4.9)
CA
Calcium (OCPC,
ortho-cresolphthalein
complexone)
mmol/l CS 1 0.8 1.1 0.7 0.9 1.1 x 0.9 (1.5)
MG Magnesium (xylidyl blue
method) mmol/l CS 1 0.7 0.7 1.0 x 1.1 (2.6)
PHOS Phosphorus (molybdate,
UV) mmol/l CS 1 x 1.1 x x 1.4 x 4
Protein assays
GPROT α1-acid-glycoprotein (TIA,
Tina-quant a) g/l HS Pool 0.7 x 5.7
ATRYP α1-antitrypsin (TIA,
Tina-quant a) g/l x 3.0
MICGL β2-microglobulin (TIA,
Tina-quant a) μg/ml x 3.0
ASLO Antistreptolysin O (LPIA,
Tina-quant a) IU/ml HS Pool 0.6 1.0
C3c Complement protein C3c
(TIA, Tina-quant a) g/l HS Pool x 1.3
C4 Complement protein C4
(TIA, Tina-quant a) g/l x x
CPLAS Ceruloplasmin (TIA,
Tina-quant a) g/l x
CRP C-reactive protein (TIA,
Tina-quant a) mg/l HS Pool x 0.8 x x 1.2 1.3 26.3
FERR Ferritin (LPIA, Tina-quant
a) μg/l HS Pool 2.3 7.5
HBA1C% Glycated haemoglobin A1c
(TIA, Tina-quant a) %H S P o o l 1 . 1
HGLOB Haptoglobin (TIA,
Tina-quant a) g/l HS Pool 0.9 1.1 x 10.2
IGG Immunoglobulin G (TIA,
Tina-quant a) g/l CS 1 x 2.5 2.0 2.6 1.9 1.9 (3.7)
IGA Immunoglobulin A (TIA,
Tina-quant a) g/l CS 1 x 1.5 0.8 x 1.1 2.2 (3.8)
IGM Immunoglobulin M (TIA,
Tina-quant a) g/l CS 1 x 1.7 1.7 x 1.3 2.3 (5.4)
IGE Immunoglobulin E (TIA,
Tina-quant a) μg/l x x
KAPPA Kappa (TIA, Tina-quant a) g/l xPaolo Mocarelli et al. 5
Table 1: Continued.
Assays Method Units Material Lab 1
CV%
Lab 2
CV%
Lab 3
CV%
Lab 4
CV%
Lab 5
CV%
Lab 6
CV%
Qual-Spec
CV%∗
LAMBD Lambda (TIA, Tina-quant
a) g/l x
MYO Myoglobin (TIA,
Tina-quant a) μg/l x
PALB Prealbumin (TIA,
Tina-quant a) IU/ml HS Pool 2.2 5.5
RF Rheumatoid factor (LPIA,
Tina-quant a) IU/ml HS Pool 0.5 0.8 0.6 0.9 4.3
TRANS Transferrin (TIA,
Tina-quant a) g/l CS 1 x 1.5 1.4 x 1.9 x 1.5
TDM assays
CARB Carbamazepine (CEDIA) μmol/l x
DIG Digoxin (LPIA) nmol/l HS Pool 2.0 3.8 (4.7)
GENT Gentamicin II (CEDIA) μmol/l x
NAPA NAPA (CEDIA) μmol/l x
PHENO Phenobarbital II (CEDIA) μmol/l x
PHNY Phenytoin II (CEDIA) μmol/l x
PROC Procainamide (CEDIA) μmol/l x
SAL Salicylate (iron complex) mmol/l x
THEO Theophylline II (CEDIA) μmol/l x
VALP Valproic Acid II (CEDIA) μmol/l HS Pool 2.0 6.4
Urine assays
NA Sodium
(ISE-indirect)-urine mmol/l HU
Pool 0.4 0.6 0.4 0.6 14.4
K Potassium
(ISE-indirect)-urine mmol/l HU
Pool 0.4 0.8 0.4 1.2 9.0
CL Chloride
(ISE-indirect)-urine mmol/l HU
Pool 0.8 1.3 0.6 0.6
AMY Amylase liquid-urine U/l HU
Pool 0.7 x
CREAJ Creatinine Jaﬀ´ e( r a t e
blanked)-urine μmol/l HU
Pool 0.8 1.0 1.2 5.5
CREA Creatinine (enzymatic,
plus)-urine μmol/l HU
Pool 0.9 5.5
GLU H Glucose (hexokinase)-urine mmol/l HU
Pool xx
UREA UREA/BUN (UV,
kinetic)-urine mmol/l HU
Pool 1.9 1.2 1.4 1.5
UA Uric Acid (PAP,
plus)-urine μmol/l HU
Pool 0.9 0.9 0.7 x
CA
Calcium (OCPC,
ortho-cresolphthalein
complex.)-urine
mmol/l HU
Pool 3.0 1.6 x 13.1
MG Magnesium (xylidyl blue
method)-urine mmol/l HU
Pool 1.0 x 19.2
PHOS Phosphorus (molybdate,
UV)-urine mmol/l HU
Pool 1.2 1.6 x 9.0
U/CSF Protein in
urine/CSF(turbidim., rate) g/l HU
Pool 0.8 x 0.7 17.8
MAU A l b u m i ni nu r i n e( T I A ,
Tina-quant a) mg/l HU
Pool 1.3 x 18
Immunochemistry assays
T3 Triiodothyronine nmol/l CS Pool x 1.4 x 0.8 4.0 (4.7)6 Journal of Automated Methods and Management in Chemistry
Table 1: Continued.
Assays Method Units Material Lab 1
CV%
Lab 2
CV%
Lab 3
CV%
Lab 4
CV%
Lab 5
CV%
Lab 6
CV%
Qual-Spec
CV%∗
T4 Thyroxine nmol/l CS Pool 2.7 x 1.5 3.4 (4.1)
FT3 Free triiodothyronine pmol/l CS Pool 1.5 2.0 4.0
FT4 Free thyroxine pmol/l CS Pool x 1.7 x x 0.9 3.8
TSH Thyroid-stimulating
hormone, thyreotropin mIU/l CS Pool x 2.1 0.8 1.1 1.1 0.6 8.1
DIGIT Digitoxin nmol/l CS Pool 2.5
DIGO Digoxin nmol/l CS Pool 2.8 3.8 (4.7)
PROBNP N-terminal B-type
natriuretic peptide pmol/l HS Pool 0.5
TNT Troponin T μg/l CS Pool 1.0 1.1
FERR E Ferritin μg/l CS Pool x x 2.1 0.9 1.6 7.5
FOLAT Folate nmol/l CS Pool x x x 3.9 1.7
B12 Vitamin B12 pmol/l CS Pool 1.8 x x 2.6
AFP α1-fetoprotein μg / l C S P o o l xx0 . 9 x1 . 8
CA 125 Cancer antigen 125 kU/l CS Pool x x x 0.9 1.0 6.8
CA 153 Cancer antigen 15-3 kU/l CS Pool 1.1 x x x 2.6
CA 199 Cancer antigen 19-9 kU/l CS Pool 0.9 x x 12.3
CEA Carcinoembryonic antigen μg/l CS Pool x x 1.2 1.3 4.6
TPSA Total prostate-speciﬁc
antigen μg / l C S P o o l xx0 . 5 x2 . 3 9 . 1
FPSA Free prostate-speciﬁc
antigen μg/l CS Pool 0.8 1.0 x
CORT Cortisol nmol/l CS Pool 1.6 1.0 x 7.6
DHEA-S Dehydroepiandrosterone
sulfate μmol/l CS Pool 2.5 x 1.7
E2 Estradiol pmol/l CS Pool 1.6 1.7 x 1.7 10.9
FSH Follicle stimulating
hormone IU/l CS Pool x 0.9 1.3 x 5.1
HCG + β Human chorionic
gonadotropin + β-subunit IU/l CS Pool 1.8 1.2 1.2
LH Luteinizing hormone IU/l CS Pool x 1.1 x x 6.2
PROG Progesterone nmol/l CS Pool x 1.2 9.8
PRL Prolactin mIU/l CS Pool x 1.2 x x 3.5
PTH Parathyroid hormone pmol/l x x x
INS Insulin pmol/l CS Pool 2.3 1.6 7.6
TESTO Testosterone pmol/l 1.4 1.6 x 4.4
∗ References [10, 11], values in italics: from Ric´ os et al. [12]; values in parentheses: interim quality speciﬁcations.
processed at each laboratory. The reagents for MODULAR
system were the respective system packs from Roche Diag-
nostics.Thecalibrationofthetestswasdoneaccordingtothe
requirements set by the manufacturer using the calibration
materials from Roche Diagnostics. The daily quality control
was performed with control sera also provided by the manu-
facturer.
Depending on the analyte, either control material or
human specimen pools were used for the imprecision and
routine simulation imprecision experiments. Samples for the
workﬂow experiments included serum, heparinized plasma
and urine from the daily routine.
The performance evaluation was supported by CAEv, a
program for Computer Aided Evaluation [4]. This program
allows the deﬁnition of experiments, the sample and test re-
quests, on-line/oﬀ-line data transmission, and the immedi-
ate data validation by the evaluators.
3. EVALUATION PROTOCOL
3.1. Within-runimprecision
Two control materials (serum, urine) with diﬀerent con-
centrations of the analyte (or, for some analytes, a humanPaolo Mocarelli et al. 7
Table 2: Overview of processed workloads at the participating laboratories. (For explanation see materials and methods section, workﬂow
study.)
Site SWA
conﬁg.
Analytes
processed
Averagere-
quests per
sample
Sample distribution Total number of
samples/ requests
Routine compared
1P E
3o n I S E
11 (1–36)
CC only: 232 299 samples Yes,
30 on P Eo n l y : 1 8 3281 requests P800 + E170
11 on E CC + E: 49
2P P E
3o n I S E
11 (1–27)
CC only: 381 555 samples Yes,
41 on PP Eo n l y : 1 4 5839 requests PP + 2∗E2010
15 on E CC + E: 160
4 on E2010
3P E
3o n I S E
9 (1–35)
CC only: 287 399 samples No
28 on P Eo n l y : 3 3 3422 requests
17 on E CC + E: 79
4P E
3o n I S E
8 (1–21)
CC only: 318 531 samples No
26 on P Eo n l y : 8 7 4003 requests
16 on E CC + E: 126
5P P E
3o n I S E
6 (1–22)
CC only: 369 573 samples Yes,
39 on PP Eo n l y : 6 3 3668 requests H917 + H747 + 3 instr. with CLIA + RIA
19 on E CC + E: 141
6D P E
3o n I S E
9 (1–29)
CC only: 1428 1951 samples No
12 on D Eo n l y : 7 7 16805 requests
25 on P CC + E: 446
3o n E
(E2010 = Elecsys 2010; Elecsys is a trademark of a member of the Roche group; CLIA = chemiluminescence immunoassay; RIA = radio immunoassay.)
specimen pool at the diagnostic decision level) were used.
The experiment was performed on two days with 21 aliquots
per run.
3.2. Precisioninasimulatedroutinerun
Experiments for routine simulation are designed for func-
tionality testing of an analytical system in the clinical labora-
tory. The protocol [5] has proven to be a useful tool during
various analyser evaluations [6].
This particular experiment tests for potential systematic
or random errors by comparing the imprecision of the ref-
erence results (standard batch, n = 15) with results from
samples run in a pattern simulating routine sampling (ran-
domized sample requests, n>10). The randomized sample
requests were simulated in CAEv [4] according to each labo-
ratory’s routine sampling pattern. The samples were control
materials or patient sample pools. The number of requests
varied with module combination, but was aimed at keeping
the analyser in operation for at least four hours. The second
and third of the three experiments processed at each site in-
cludedprovocationincidentslikereagentorsampleshortage,
b a r c o d er e a de r r o r s ,a n dv a r i o u sr e r u n s .
3.3. Samplecarryover
Potential sample related carryover was investigated using a
slightlymodiﬁedversionoftheBroughtonprotocol[7].Only
analytes with a very high physiological concentration range
were tested. Ideally, the ratio of the concentrations of the
high and low samples should be, depending on the analyte,
103 to 106. Three aliquots of a high concentration sample
(h1,h2,h3)w e r ef o l l o w e db ym e a s u r e m e n t so fﬁ v ea l i q u o t s
of a low concentration sample (l1 ··· l5)o ne a c hm o d u l e .
The sequence h1 h2 h3 l1 l2 l3 l4 l5 was repeated ﬁve times.
Each sample was measured on the ISE module ﬁrst, then
on the D and/or P module, and ﬁnally on the E170 mod-
ule, thereby insuring that reusable pipette probes were intro-
duced multiple times prior to sampling on the E170 mod-
ule, where disposable (nonreusable) pipette tips are used.
If a carry-over eﬀect from the ISE and D/P module sam-
ple probes exists, the l1 will be the most inﬂuenced, and the
l5 will be the least inﬂuenced aliquot when measured on E-
module. The carry-over eﬀects were compared with the im-
precision of the low concentration samples and the diag-
nostic relevance of the respective E-module assays. Potential
sample carryover of the following analytes was tested: AFP,
CEA, ferritin, anti-HAV, HBsAg, hCG + ß, and t-PSA.
3.4. Workﬂowstudy
The participating sites performed this study to investigate
whether or not MODULAR system met their routine labo-
ratory speciﬁc needs, especially for improved eﬃciency. As
shown in Table 2, module combination, analyte assignment,
tests per sample, numbers of samples, samples per module,8 Journal of Automated Methods and Management in Chemistry
Table 3: Sample related carryover with high priority test option oﬀ. With high priority test option on, sample carryover cannot occur. (For
explanation see results section, sample-related carryover.)
Analyte Expected
values
10% of lower
decision level
Lower detec-
tion limit
Ratio high :
low
Max. diﬀ low1–
low5(if >2SD) Material
Relevant
Carry-
over, high
priority oﬀ
Relevant
Carry-
over, high
priority on
AFP <6.2μg/l 0.62μg/l 0.6μg/l 40871 0.62 Native yes No
CEA <4.6μg/l 0.46μg/l 0.2μg/l 16197 7.64 Spiked yes No
PSA <4μg/l 0.4μg/l 0.002μg/l 756 0.20 Spiked yes No
Ferritin ∼15–400μg/l 1.5μg/l 0.5μg/l 969 2.00 Spiked no No
HCG + β< 5mIU/ml 0.5mIU/ml 0.1mIU/ml 117000 1.30 Native yes No
a-HAV <20IU/l 2.0IU/l 3.0IU/l 1184 0.25 Native no No
HbsAg <1.0COI 0.1 COI 285106 0.44 Native yes No
and tests per module, were very diﬀerent at each laboratory.
Threemethodswereusedtocapturethetestrequestsonsam-
ples so that the same testing could be repeated on MODU-
LAR system. Test requests were either downloaded from the
laboratory’s LIS to CAEv, captured directly by CAEv from
several analysers during routine operation or CAEv provided
a “characteristic” request list by simulation based on typical
testfrequenciesandproﬁlesofthelaboratory.Inallcases,the
same sample set, usually a predeﬁned substantial portion of
a day’s workload was processed on MODULAR system.
Samples were loaded on MODULAR system chronolog-
ically as they appeared in the lab to mimic the laboratory’s
routine pattern of receiving samples. All relevant time steps
and workload related activities like sample and reagent han-
dling,instrumentpreparation,loadingandreloadingofsam-
ple racks, and technologist time (both hands-on and walk-
away) were measured.
3.5. Practicability
Practicability of the system was assessed throughout the
study. A questionnaire—a supplement to the general ques-
tionnaire [8], which was previously used for the assessment
of the single modules—was designed especially for a consol-
idated sample working area. This allowed for a standardized
grading with the main focus on aspects of clinical chemistry
and immunochemistry consolidation and new software fea-
tures.
3.6. Expectedperformance
The protocol included expected performance criteria which
wereagreeduponattheevaluators’ﬁrstmeeting.Thecriteria
for imprecision were based on state-of-the-art performance,
routine requirements of the laboratories, and statistical error
propagation [9].
4. RESULTS
Across all experiments, 236000 results from 32400 samples
were generated using 93 methods.
4.1. Imprecision
The within-run imprecision met the expected performance
criteria at virtually all sites. Typical within-run CVs for the
enzymeandsubstrateanalyteswere1to2%,fortheionselec-
tive electrode (ISE) methods 0.5%, for the speciﬁc proteins
and drug analytes 1 to 3%, for the urine chemistry methods
1 to 2%, and for the heterogeneous immunoassays (with the
indication: thyroid, cardiac, anaemia, tumour markers and
f e r t i l i t y )1t o3 %( Table 1).
4.2. Functionalitytesting
Thesixlaboratoriesperformed44668 determinations during
the random part of the routine simulation covering 87 ana-
lytes in 733 series. CVs obtained from the precision in a sim-
ulated routine run experiment for the various assay groups
(ISEs, enzymes/substrates, urine analytes, proteins/TDMs,
and heterogeneous immunoassays) were summarized in dis-
tribution diagrams for the reference (batch part) and ran-
dom part (see Figure 2). Out of all 733 series, 13 (1.8%)
showed higher CVs than the expected limit in the random
part (9 in the enzyme/substrate group, 2 in the urine and the
immunoassay groups). Seven of these CVs were only mod-
erately increased (1 to 2% higher than the limit). Of the
remaining 6 series (5.3 to 22.8% CV), the highest CV was
caused by an unexplainable, nonreproducible outlier with a
verylowresultinoneseriesofthealbumininurinetest.With
the outlier removed, the CV was 1.2%. In all cases, the higher
CVswereobservedinonlyoneofthethreesimulatedroutine
series per laboratory (with tests like lipase, uric acid, albu-
min in urine and CA125) and there was no association with
any malfunction of the instrument or reagent. A software is-
sue associated with the E-module masking/unmasking dur-
ing a provocation was also identiﬁed during these experi-
ments (shift of the results with the FT3 assay).
4.3. Sample-relatedcarryover
Table 3 summarizesthecarry-overeﬀects seen when the high
priority settings were intentionally turned oﬀ for a groupPaolo Mocarelli et al. 9
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Figure 2: Precision in a simulated routine run; distribution of 733 within-run CVs in reference (batch) and random parts; replicates n
in reference part 15 as follows: (i) expected performance limit for within-run imprecision (solid line) (ii) expected performance limit for
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Figure 3: SPT on MODULAR system and dedicated routine anal-
ysers representing 40% of a daily routine workload.
of tests that were considered high risk for sample carryover.
Onlyresultsfromlaboratorieswiththehighestconcentration
ratio (high/low) are included in the table. For the 7 assays for
whichweexpectedtoseesample-relatedcarryoverbecauseof
the wide dynamic range of the analytes, our testing indicated
potentially clinically relevant problems with 5 (AFP, CEA,
HBsAg, HCG + ß, and t-PSA). By utilizing the “high prior-
ity test” option, samples with requests for these assays, which
also had requests for ISE, D, and/or P module tests, were au-
tomatically processed at the E-module ﬁrst, eliminating the
possibility for carryover to occur for these samples and tests.
In the other two (ferritin and anti HAV), neither criterion
for carryover was met (more than 10% of the (lower) medi-
cal decision level, or exceeding the 2 SD value). According to
investigationsofthemanufacturer,twoadditionalcarry-over
sensitive infectious disease assays were identiﬁed: anti-HBs
and anti-HBc.
4.4. Workﬂow
T h em o d u l ec o m b i n a t i o n s(  PE ,  PPE ,  DPE )a n dt e s t
menu conﬁgurations used at the diﬀerent laboratories were
selected to meet their speciﬁc workload demands. An
overview is presented in Table 2. To reﬂect true routine con-
ditions, the samples were placed on the system in a se-
quence mimicking the original arrival pattern in the labora-
tory, rather than continuously, to test the system’s potential
sample loading capacity. The resulting cumulative through-
put was up to 800 results/hour using  PE  module combi-
nations and up to 1580 results/hour for  PPE  module com-
binations. A throughput of approximately 2160 results/hour
was yielded on the  DPE  module combination in labora-
tory 6. In most of the laboratories, the number of samples
processed was not enough to reach the system’s maximum
throughput capacity.
In addition to throughput, we looked carefully at sample
processing time (SPT), the time between sample registration
(barcode reading on the instrument) and the time the last
0:00
0:10
0:20
0:30
0:40
0:50
1:00
1:10
1:20
1:30
T
i
m
e
o
n
a
n
a
l
y
s
e
r
f
r
o
m
r
e
g
i
s
t
r
a
t
i
o
n
t
o
l
a
s
t
r
e
s
u
l
t
(
h
:
m
i
n
)
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
1
1
0
1
1
1
1
1
2
1
1
3
1
1
4
1
1
5
1
1
6
1
1
7
1
1
8
1
1
9
1
Diagram shows only a part of the whole workload
Sample number
ISE rerun
Pr e r u n
Er e r u n
Figure 4: SPT with focus on availability of rerun results.
resultforthatsampleisproduced.NotethatSPTdiﬀersfrom
sample turnaround time (TAT), a commonly used term to
describe the time period from when the samples arrive in the
laboratory and the availability of the last result.
The following mean sample processing times were found
for the diﬀerent sample groups in ﬁve laboratories:
(i) 13–18 minutes for samples with general chemistry
requests only (ISE + P or ISE + P1 + P2),
(ii) 22–28 minutes for samples with immunoassay re-
quests only (E),
(iii) 29–38 minutes for samples with combined requests
(ISE + P + E or ISE + P1 + P2 + E).
The mean SPTs obtained with a  DPE  combination were
comparable: 16 minutes for ISE + D + P, 26 minutes for E,
and 27 minutes for ISE + D + P + E.
We compared SPT of MODULAR  PPE  with the cur-
rent six dedicated routine analysers for a predetermined time
period, representing approximately 40% of a day’s workload
in laboratory 5. Figure 3 shows that the time to results for
samples with clinical chemistry requests on MODULAR sys-
tem is comparable with that of the dedicated routine anal-
ysers (mean time 15 minutes, 80th percentile 20 minutes,
maximum 38 minutes). Samples with combined requests
for both clinical chemistry and immunochemistry were pro-
cessed faster (mean time 34 minutes, 80th percentile 40 min-
utes, maximum 1 hour) than on the dedicated analysers
(mean time 46 minutes, 80th percentile 58 minutes, maxi-
mum 1.8 hours).
Depending on test, module and number of racks waiting
in the rerun buﬀer, rerun results are reported 10–35 minutes
after availability of ﬁrst results. An example of typical pro-
cessing times to ﬁrst results and to ﬁnal results (including
rerun samples) is shown in Figure 4.
MODULAR SWA supports “reﬂex testing,” if the lab-
oratory information system (LIS) oﬀers this functionality.
Frequently practiced for certain indication ﬁelds, this fea-
ture allows the automatic request of a further analyte, if aPaolo Mocarelli et al. 11
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Figure 5: SPT with focus on reﬂex testing.
predeﬁned concentration or concentration range of the orig-
inally requested analyte is exceeded. Examples are as follows:
If TSH < 0.27 or > 4.2mIU/L, FT4 is determined in addition,
if PSA > 4.0μg/L, free PSA is also measured and so on. Even
though it may no longer be as clinically relevant, reﬂex test-
ing functionality was assessed using a combination of P-and
E-requests: CK → CK-MB(enzymatic) +T n T .T h eS P Tf o rs u c h
a sample with two additional reﬂex tests was increased by 30
to 55 minutes (Figure 5).
Does the sample carry-over setting, which tags the assay
in question automatically as high priority by the system, in-
ﬂuence the SPT? We compared samples having combined re-
quests (on P- and E-module) with and without high prior-
ity assays. With auto rerun oﬀ, there was no result delay. The
processing times were increased by 10–15 minutes with auto
rerun activated, where processing on P module was delayed
until ﬁnal E-module results were available.
Maintenance and troubleshooting are activities which
may also considerably inﬂuence the daily workﬂow. For a
modular system, the question arises whether the entire sys-
tem or only the aﬀected module is blocked in order to rem-
edy a problem after, for example, a sampling stop alarm. This
type of alarm results in the module discontinuing pipetting
of samples. The diﬀerent time steps for two such alarms were
monitored on a  PPE  combination at one site. For a pro-
voked tip/vessel pickup-error on the E-module, the elapsed
time from getting the alarm, allowing the module to ﬁnish
the tests in process, taking the module down, then ﬁxing the
problem, and getting the module back into operation was a
total of 35 minutes; for a provoked abnormal cap mechanism
movement 22 minutes. While the E-module was unavailable,
the ISE and P-modules continued to process samples, and
samples requiring E-module tests were stored in the rerun
buﬀertoberunautomaticallywhentheE-modulecameback
online.
An important aspect of instrument consolidation on a
single platform is reduction in personnel hands-on time. In
laboratory 5, we compared hands-on time associated with
MODULARsystemwiththatofthe6existingdedicatedanal-
ysers. As shown in Figure 6, the operators saved about 10
hours based on the sample workload; the main contribution
was sample handling time. MODULAR system was operated
by 1 technologist while the 6 dedicated analysers required 3
persons.
One of the participating laboratories (laboratory 1) sim-
ulated a workﬂow using MODULAR system as a dedicated
immunoassay analyser. Tests included 24 homogeneous tests
(10 speciﬁc proteins, 6 therapeutic drug tests, and 8 drugs
of abuse tests) on P-module and 18 heterogeneous assays
(thyroid, cardiac, anaemia, and tumour markers) on the E-
module, with samples loaded in a simulated routine-type
pattern. The average sample processing times for the vari-
ous request patterns were comparable with those mentioned
previously (<35 minutes).
4.5. Practicability
With the aid of a questionnaire, the practicability of MOD-
ULAR system was graded as equally good (23% of all scores)
or even better (68%) compared to the evaluators’ currently
used routine analysers.
5. DISCUSSION
Overall assessment of the experiments can be rated as posi-
tive.Itwastheﬁrsttimethattherewasanopportunityduring
an evaluation to combine various laboratory segments with
an extensive menu for general chemistry, speciﬁc proteins,
drugs, and immunochemistry on one platform.
5.1. Imprecision
Since analytical performance was previously veriﬁed for the
single MODULAR systems [2, 3], this study did not include
extensive analytical performance data. However, one or two
imprecisionrunswereprocessedforrepresentativetestsfrom
each analyte group to assure that the system was perform-
ing correctly. Typical within-run CVs of 1 to 3% across the
menu of nearly 90 tests were all within the expected perfor-
mance and can be rated as excellent. We can emphasize here
that the heterogeneous immunoassays performed with the
electrochemiluminescence technology showed reproducibil-
ity similar to the general chemistry tests and well within clin-
ical demands (see Table 1)[ 10–12].
5.2. Functionality
The overall low CVs for all analyte groups in the simulated
routine imprecision runs proved that general chemistry and
immunochemistry worked very well together, and, that even
under simulated stress routine conditions, there was no in-
dication of systematic or random errors. The 6 high CVs
of the routine simulation experiment occurred in only one
of 3 runs per laboratory, and there was no indication that
the deviant results were reproducible. The routine simula-
tion precision experiments demonstrated good performance
and full functionality of the instrument. Because of the sen-
sitivity of the experimental design, it was possible to iden-
tify one severe instrument problem associated with the E-
module masking/unmasking feature during provocation of
theanalyser.Theerrorwascorrectedwithasoftwareupgrade12 Journal of Automated Methods and Management in Chemistry
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Figure 6: Hands-on time on MODULAR system compared to dedicated routine analysers representing 40% of a daily routine workload.
and the correct implementation was conﬁrmed with further
routinesimulationrunsatallsites.Throughoutallotherrou-
tine environment testing, the instruments reacted correctly
based on the routine simulation data.
5.3. Samplecarryover
MODULAR system runs with new user software, combin-
ing and unifying the functionality and features of the sin-
gle modules and optimizing the processing of clinical chem-
istry and immunochemistry requests. For example, sample
carryover to some sensitive immunoassays cannot occur due
to intelligent sample processing whereby samples with re-
quests for carryover sensitive assays, referred to as high prior-
ity tests, are processed at the immunology module (E) ﬁrst.
High priority tests are user-deﬁnable and do not delay pro-
cessing of other samples, even samples in the same sample
rack.AsmentionedintheResults section,processingsamples
with high priority requests with “Auto-rerun” activated took
15 minutes longer in comparison to the usual samples. This
however, reduced potential risks and eliminated any manual
operator intervention. If there are only very few specimens
with concentrations above the upper measuring range limit
of the high priority tests, the laboratory manager can decide
to deactivate auto-rerun without any high risk of quality loss
but with acceleration of result availability.
5.4. Workﬂow
Workﬂow depends strongly on the laboratory environment,
the sample loading pattern, and on the MODULAR conﬁgu-
ration. Our studies show that MODULAR system oﬀers the
ﬂexibility to ﬁt and meet the requirements of the individual
laboratory. The variations in throughput at the diﬀerent sites
can be explained by the lab-speciﬁc workloads and sample
loading patterns.
The processing times for the sample groups with general
or immunochemistry requests were similar to those known
from the respective stand-alone modules, thus showing that
there was no relevant increase when combining photomet-
ric/ISE and E-modules. In other words, the immunochem-
istry module did not slow down the clinical chemistry mod-
ules. An average processing time of approximately 35 min-
utes for the combined g r o u pw a sr a t e da sb e i n gv e r ya c c e p t -
able, bearing in mind that those samples were either mea-
sured sequentially on diﬀerent routine instruments or re-
quired additional hands-on times for splitting/aliquoting in
theroutinewiththecurrentroutineinstrumentation.Infact,
when these additional times were included, as done in one
laboratory, the mean sample TAT decreased by three hours
(from 3.5 to 0.5 hours) using MODULAR system.
One laboratory used the  PE  combination for simulat-
ing a dedicated immunoassay analyser covering various lab-
oratory segments. In this hospital there is a separate sample
collection and order process for certain analytes, which are
presently performed on a variety of single analysers. There-
fore, sample splitting is not necessary. The current dedicated
analysers for protein determinations, for drug monitoring or
tumour marker measurements could be replaced by a con-
solidated workstation, so that only one operator would be
needed to perform these various immunoassays. The labo-
ratory management assessed a 30 to 50% reduction of man-
power for this work on MODULAR system.
During the daily routine, a certain percentage of as-
says (usually <5%) need a repetition of the analysis, be-
cause the measuring range or a deﬁned repeat limit basedPaolo Mocarelli et al. 13
on laboratory policy is exceeded. The portion of repeat mea-
surementsduetoanalyticalrangelimitationsonMODULAR
system is usually smaller than 0.5% [2]. MODULAR system
oﬀers a user selectable automatic rerun feature, which can be
activated or deactivated for each test.
The advantages of automatic rerun—no need for sam-
ple tracking, retrieval, elimination of manual sample predi-
lution, and no manual reloading—not only increased safety
of results by minimizing possible human error, but also re-
duced processing and hands-on times.
Also, the fact that MODULAR system supports reﬂex
testing simpliﬁes the workﬂow. It is not necessary to wait for
the result validation and the conﬁrmation from the ward to
perform the additional reﬂex assay. This is especially impor-
tantforoutpatientssincethisprocedurecouldavoidasecond
hospital visit. Even if samples are held for further tests, reﬂex
testing is better than the alternatives—measuring for all tests
at the start or manual intervention to locate and transport
the samples. When including the beneﬁts of automatic rerun
analysis and reﬂex testing, results were available within 30 to
70 minutes.
Since the time of this evaluation, the use of MODULAR
system has conﬁrmed this data during a long period of rou-
tine work. When comparing the hands-on times captured at
the diﬀerent sites over one to two days, MODULAR system
yielded a clear advantage. Monitoring over an extended pe-
riod would be necessary to obtain more extensive data, but
this exceeded the scope of the study. Nevertheless, it is ob-
vious that there is a potential of saving personnel capaci-
ties since fewer instruments need fewer persons for oper-
ation. MODULAR system requires a skilled operator sim-
ilar in qualiﬁcation to that of the existing analysers com-
pared in this study. However, this person must also be able to
cope with the validation of a large amount of data produced
within a short time or have autoveriﬁcation available.
5.5. Practicability
The practicability of MODULARsystemmet or exceeded the
requirements of all participating laboratories for 91% of all
attributes rated. An opportunity for improvement was seen
in the time required to prepare the analyser for routine use
even though this was one half to three quarters of the time
required for the dedicated routine analysers. Apart from the
QC measurements which were processed directly before rou-
tine sampling start, the ﬂexibility of MODULAR system with
background maintenance features allows other tasks to be
performed at any suitable time throughout the shift. Com-
pletion of initial QC measurements for the extended menu
processed at the diﬀerent sites took an average 30 minutes.
Themainadvantagementionedbytheevaluatorswasthe
consolidation eﬀect resulting in a simpliﬁed workﬂow with a
reduction of instruments, reduced overall processing time,
reduced hands-on time, and increased eﬃciency without in-
creasing staﬃng, yet maintaining or even improving quality.
6. CONCLUSION
Our experience with the MODULAR ANALYTICS SWA in-
dicates that both functionally and practically the analyser is
a favourable addition to the clinical laboratory. Each of the
various module conﬁgurations included in this study is eas-
ily and eﬃciently managed routine and nonroutine tasks in
the simulated routine scenarios. Overall, samples with com-
binedrequestsrunninginroutineworkloads,fromamenuof
about50assays,wereprocessedinapproximately35minutes;
30 to 70 minutes including reruns and reﬂex testing. We saw
no negative eﬀects in the quality or timely reporting of test
results when combining general clinical chemistry with het-
erogeneous immunochemistry assays on the same analyser.
In fact, we found that eﬃciency was improved, and, in some
cases substantially decreasing sample turn-around time, op-
erator hands-on time, and personnel, while maintaining or
improving the quality of laboratory processes.
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